Bukwang Pharmaceutical Co., Ltd. (003000) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Bukwang Pharmaceutical Co., Ltd. (003000:KRX), powered by AI.

Current Price
₩4,775
P/E Ratio
37.5
Market Cap
471.1B
Sector
Healthcare
What is the Bukwang Pharmaceutical Co., Ltd. stock price forecast?

Bukwang Pharmaceutical Co., Ltd. is currently trading at ₩4,775. View real-time AI analysis on Alpha Lenz.

What is Bukwang Pharmaceutical Co., Ltd. insider trading activity?

View the latest insider trading data for Bukwang Pharmaceutical Co., Ltd. on Alpha Lenz.

What is Bukwang Pharmaceutical Co., Ltd.'s P/E ratio?

Bukwang Pharmaceutical Co., Ltd.'s P/E ratio is 37.5.

Bukwang Pharmaceutical Co., Ltd.

KRX · 003000
₩4,775+300(+6.70%)Market closedKRX regular session 09:00–15:30 KST
Ask about Bukwang Pharmaceutical Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Bukwang Pharmaceutical Co., Ltd. trades at a P/E of 37.5 (premium valuation) with modest ROE of 4.3%.

Ask for details

Company Overview

Bukwang Pharmaceutical Co., Ltd. is a key player in the pharmaceutical industry engaged in the research, development, manufacturing, and marketing of a wide range of pharmaceutical products. Established in South Korea, the company focuses on producing medications that address various therapeutic categories, including neurology, gastroenterology, and infectious diseases. Bukwang is committed to advancing healthcare through innovative solutions and has invested significantly in R&D efforts aimed at developing proprietary drugs and novel treatments. The company's products cater to both domestic and international markets, impacting medical practitioners, healthcare institutions, and patients globally. Bukwang Pharmaceutical holds a significant position in the healthcare sector due to its emphasis on scientific research and development, strategic collaborations with global pharmaceutical entities, and efforts to expand its presence in emerging markets. Its contributions are crucial for addressing unmet medical needs and enhancing the quality of life for patients by providing access to effective and safe pharmaceuticals.

CEO이제영
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees606

Company Statistics

FY 2025

Profile

₩471,123,804,025Market Cap
₩200,714,183,690Revenue
98.66MShares Out
606Employees

Margins

45.79%Gross
12.46%EBITDA
7.06%Operating
3.18%Pre-Tax
6.19%Net

Valuation

37.52P/E
1.38P/B
2.35EV/Sales
18.21EV/EBITDA
45.88P/FCF

Growth (CAGR)

1.68%Rev 3Yr
3.42%Rev 5Yr
N/AOp Inc 3Yr
28.59%Op Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

2.93%ROA
4.30%ROE
2.42%ROIC

Financial Health

₩96,208,176,680Cash & Cash Equivalents
₩39,154,359,500Net Debt
39.70%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Bukwang Pharmaceutical Co., Ltd. (ticker: 003000) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 606 employees. Market cap is $471.1B.

The current price is ₩4,775 with a P/E ratio of 37.52x and P/B of 1.38x.

ROE is 4.30% and operating margin is 7.06%. Annual revenue is $200.7B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Bukwang Pharmaceutical Co., Ltd. (003000) Stock Forecast 2026 ₩4,775 — Price, Financials & Analyst Targets | Alpha Lenz